Evotec & Apeiron Ink Discovery Pact for Anti-tumor Immune Therapy

Evotec and Apeiron Biologics have entered into a discovery project on the Cbl-b target for an anti-tumor immune therapy.

Evotec and Apeiron Biologics have entered into a discovery project on the Cbl-b target for an anti-tumor immune therapy.

Under the partnerships established by the two Germany-based companies, Evotec will apply its technologies in cellular assay development and ultra-high throughput screening (uHTS) to identify biologically active molecules from its corporate library that interact with Cbl-b.

Cbl-b plays a role in both the adaptive and the innate immune system and its manipulation can potentially enhance anti-tumor activities for both tumor antigen-specific cells and general features of tumor cells.

The aim of the collaboration is to use the compounds identified